AstraZeneca Annual Report and Form 20-F Information 2015
2015 was an exceptional year for AstraZeneca, as we made significant progress in meeting both our near- and longer-term strategic goals.
Pascal Soriot, Chief Executive Officer
Therapy Areas
AstraZeneca is a global, science-led biopharmaceutical business with an on-market portfolio in our chosen therapy areas.
Respiratory, Inflammation and Autoimmunity
$4,987m
Product Sales (2014: $5,063m, 2013: $4,677m)
Highlights
- Respiratory sales up by 7%, including 25% in Emerging Markets, before completion of the acquisition of Takeda's respiratory business
- Sales of Symbicort down by 3%
Cardiovascular and Metabolic diseases
$9,489m
Product Sales (2014: $9,802m, 2013: $8,830m)
Highlights
- Brilinta/Brilique sales up by 44%, including 64% in the US
- Diabetes sales up by 26%, including 76% in Emerging Markets
- Sales of Crestor fell by 3% reflecting competition from generic statins and pricing pressure
Oncology
$2,825m
Product Sales (2014: $3,027m, 2013: $3,193m)
Highlights
- Oncology sales up by 7%
- New Oncology included for the first time (comprising Lynparza, Iressa (US) and Tagrisso)
- Lynparza launched in 15 markets and sales of $94 million
Infection, Neuroscience and Gastrointestinal
$6,340m
Product Sales (2014: $8,203m, 2013: $9,011m)
Highlights
- Sales of Nexium declined by 26%, including 52% in the US following loss of exclusivity
- Sales of Seroquel XR fell by 12% and Synagis fell by 26%
R&D Capabilities
We have distinctive R&D capabilities in small molecules, biologics, immunotherapies, protein engineering and devices.
Main therapy areas
Respiratory, Inflammation and Autoimmunity
Cardiovascular and Metabolic diseases
Oncology
Opportunity-driven
Infection, Neuroscience and Gastrointestinal
We also have personalised healthcare and translational science capabilities.
Global presence
We have a strong global commercial presence, with strength in Emerging Markets.
North America
$10,007m
Product Sales (2014: $10,710m, 2013: $10,328m)
7,600 employees
Highlights
- Sales in the US declined by 6% reflecting entry of generic Nexium products and adverse Synagis guideline changes
- Favourable performances were delivered by Brilinta, Farxiga, Bydureon and Lynparza as well as the acquired Respiratory medicines, Tudorza and Daliresp
- Sales in Canada grew by 4%
Europe
$5,323m
Product Sales (2014: $6,638m, 2013: $6,658m)
5,900 employees
Highlights
- Sales declined by 6%
- Strong growth for Diabetes medicines was offset by generic competition facing Crestor and Seroquel XR
- 14% decline in Symbicort sales reflected adverse pricing movements driven by competition from analogues in key markets
International and Japan
$8,311m
Product Sales (2014: $8,747m, 2013: $8,725m)
21,900 employees
Highlights
- Emerging Markets revenue grew by 12% to $5,822 million, including China sales growth of 15%
- Sales in Japan grew by 4% to $2,020 million
- Opened facility in Russia
Employees
Our talented employees are committed to achieveing our Purpose in a sustainable way.
61,500 employees worldwide
8,900 employees in R&D
12,500 employees in Manufacturing and Supply
All employee numbers are approximate as at 31 December 2015.
Strategic R&D centres
Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.
Cambridge, UK
Gaithersburg, Maryland US
Gothenburg, Sweden
Progressive dividend
Our disciplined capital allocation enables commitment to a progressive dividend.
Net cash shareholder distributions increased to $3,443 million
Dividend per Ordinary Share unchanged
Life-cycle of a medicine
As a global science-led biopharmaceutical company, our activities span the entire life-cycle of a medicine from Research and Development to Manufacturing and Supply to the global Sales and Marketing of primary care and speciality care medicines that transform lives.
The Board of Directors has sought to ensure that AstraZeneca's achievements in 2015 were underpinned by strong corporate governance.
Leif Johansson, Chairman
